4P Therapeutics is a wholly owned subsidiary of Nutriband Inc, focused on the research and development of novel drug delivery technologies and therapeutics. 4P develops products that meet the needs of patients, physicians and payers. The company has capabilities for developing pharmaceutical products from pre-clinical testing to clinical manufacturing and early stage clinical development (Phase I/II).
A key company focus and area of expertise is in the development of transdermal products for currently injected compounds, including proteins, peptides, macromolecules and biologics. Transdermal delivery of commercially available drugs or biologics that are typically delivered via injection has the potential to improve safety, efficacy and therapeutic outcomes associated with these treatments.
Imagine a world with improved patient compliance, a steady drug delivery state, less frequent dosing, minimal adverse effects, less invasive treatments and problems with gastrointestinal absorption issues are avoided by eliminating the first pass metabolism.